article thumbnail

STAT+: Pharmalittle: AbbVie buys Immunogen, maker of targeted cancer drugs; Novo sues two more compounders

STAT

Elahere is among a surging class of cancer medicines called antibody-drug conjugates, or ADCs, which are designed to deliver a targeted dose of chemotherapy directly to tumor cells while sparing healthy tissues. Testing of compounded drugs from these pharmacies revealed unknown impurities up to 33%, the company claims.

article thumbnail

GlycoMimetics files patent for treating cancer and related conditions with compound of formula (i)

Pharmaceutical Technology

s groundbreaking patent for treating cancer and related conditions with Formula (I) compound. Learn how this method can reduce chemotherapy side effects and improve patient outcomes. Discover GlycoMimetics Inc.'s

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

STAT+: Pharmacists can make shortage drugs, but at what cost?

STAT

Pharmacists increasingly are being asked to make drugs in bulk for hospitals that are in short supply, and they’re even beginning to make chemotherapies. Hospitals’ reliance on pharmacist-made drugs, a practice called compounding, has risen in step with worsening drug shortages.

article thumbnail

Manual IV Compounding – a Potential Recipe for Disaster?

Omnicell

When we talked about IV room compounding, I’ll never forget them telling me, “Making IVs is not like making pizzas at the local sub shop.” ” It’s not a big deal if you mix up sausage and pepperoni on a pizza, but one misstep in manual IV compounding could be absolutely devastating to a patient.

article thumbnail

Pluvicto™ offers survival benefits for metastatic prostate cancer

European Pharmaceutical Review

The PSMAfore results are the second positive set of data for Pluvicto in a Phase III trial, after the VISION clinical trial, where PSMA–positive mCRPC patients who received Pluvicto plus standard of care (SoC) after ARPI and taxane-based chemotherapy, showed statistically significant reduction in risk of death. The PSMAfore study.

article thumbnail

US FDA approves Incyte’s merkel cell carcinoma therapy

Pharmaceutical Technology

It is also being assessed in other tumour types and along with other Incyte pipeline compounds. Zynyz monotherapy showed a 52% objective response rate (ORR) in chemotherapy-naïve patients. We continue to study the potential of Zynyz in additional tumour types and in combination with other Incyte pipeline compounds.”

FDA 98
article thumbnail

CHMP recommends Pluvicto® for treating advanced prostate cancer

European Pharmaceutical Review

Pluvicto combines a targeting compound (ligand, in this case directed to PSMA) with a therapeutic radioisotope (in this case lutetium-177). Pluvicto delivers radiation to PSMA-positive cells and the surrounding microenvironment. A Phase III trial showed Pluvicto improved survival for patients with pre-treated PSMA-positive mCRPC.